Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.
Rosati G, Cella CA, Cavanna L, Codecà C, Prisciandaro M, Mosconi S, Luchena G, Silvestris N, Bernardini I, Casaretti R, Zoratto F, Amoroso D, Ciarlo A, Barni S, Cascinu S, Davite C, Di Sanzo A, Casolaro A, Bilancia D, Labianca R. Rosati G, et al. Among authors: di sanzo a. Gastric Cancer. 2022 Jul;25(4):783-793. doi: 10.1007/s10120-022-01292-y. Epub 2022 Mar 30. Gastric Cancer. 2022. PMID: 35352176 Clinical Trial.
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, Fiorentini F, Alzani R, Carpinelli P, Di Sanzo A, Galvani A, Isacchi A, Ramanathan RK. Weiss GJ, et al. Among authors: di sanzo a. Invest New Drugs. 2018 Feb;36(1):85-95. doi: 10.1007/s10637-017-0491-7. Epub 2017 Jul 20. Invest New Drugs. 2018. PMID: 28726132 Clinical Trial.
n-3 fatty acids in patients with multiple cardiovascular risk factors.
Risk and Prevention Study Collaborative Group; Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, Marzona I, Milani V, Silletta MG, Tognoni G, Marchioli R. Risk and Prevention Study Collaborative Group, et al. N Engl J Med. 2013 May 9;368(19):1800-8. doi: 10.1056/NEJMoa1205409. N Engl J Med. 2013. PMID: 23656645 Free article. Clinical Trial.
Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice.
Rischio and Prevenzione Investigators. Rischio and Prevenzione Investigators. Trials. 2010 May 28;11:68. doi: 10.1186/1745-6215-11-68. Trials. 2010. PMID: 20509875 Free PMC article. Clinical Trial.